

# Ari M Melnick

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6259331/ari-m-melnick-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

412  
papers

29,540  
citations

88  
h-index

165  
g-index

428  
ext. papers

35,144  
ext. citations

11.1  
avg, IF

6.6  
L-index

#	Paper	IF	Citations
412	System-wide transcriptome damage and tissue identity loss in COVID-19 patients.. <i>Cell Reports Medicine</i> , <b>2022</b> , 3, 100522	18	2
411	Histone 3 Methyltransferases Alter Melanoma Initiation and Progression Through Discrete Mechanisms.. <i>Frontiers in Cell and Developmental Biology</i> , <b>2022</b> , 10, 814216	5.7	
410	Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival.. <i>Blood Cancer Discovery</i> , <b>2022</b> , 3, 50-65	7	2
409	Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia.. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabb7695	17.5	1
408	3D chromosomal architecture in germinal center B cells and its alterations in lymphomagenesis.. <i>Current Opinion in Genetics and Development</i> , <b>2022</b> , 74, 101915	4.9	0
407	Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 805195	5.7	0
406	An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. <i>Blood Cancer Discovery</i> , <b>2021</b> , 2, 70-91	7	7
405	Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-10	1.9	1
404	MALT1 Degradation with a Proteolysis-Targeting Chimera for the Treatment of Activated B-Cell Type Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2021</b> , 138, 269-269	2.2	0
403	Evolution of the Tumor Microenvironment throughout Progression and Transformation of EZH2 Mutant Follicular Lymphoma. <i>Blood</i> , <b>2021</b> , 138, 446-446	2.2	0
402	Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study. <i>Blood</i> , <b>2021</b> , 138, 413-413	2.2	0
401	BTG1 Mutation Promotes Aggressive Lymphoma Development By Lowering the Threshold to MYC Activation and Generating "Super-Competitor" B Cells. <i>Blood</i> , <b>2021</b> , 138, 359-359	2.2	0
400	Complex Structural Variation Associated with Enhancer Hijacking and Loss of Tumor Suppressors in Mantle Cell Lymphoma. <i>Blood</i> , <b>2021</b> , 138, 675-675	2.2	
399	Sirtuin 3 Inhibition Targets AML Stem Cells through Perturbation of Fatty Acid Oxidation. <i>Blood</i> , <b>2021</b> , 138, 2240-2240	2.2	
398	Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts.. <i>American Journal of Hematology</i> , <b>2021</b> ,	7.1	1
397	Cyclin D3 drives inertial cell cycling in dark zone germinal center B cells. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	17
396	KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. <i>Blood</i> , <b>2021</b> , 138, 370-381	2.2	16

395	Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. <i>Nature Communications</i> , <b>2021</b> , 12, 1660	17.4	60
394	An Esrrb and Nanog Cell Fate Regulatory Module Controlled by Feed Forward Loop Interactions. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 630067	5.7	1
393	Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> , 64, 4333-4358	8.3	6
392	Non-oncogene Addiction to SIRT5 in Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , <b>2021</b> , 2, 198-200	7	0
391	Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML. <i>Blood</i> , <b>2021</b> , 138, 160-177	2.2	2
390	Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. <i>Blood</i> , <b>2021</b> , 138, 948-958	2.2	7
389	Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL). <i>Current Cancer Drug Targets</i> , <b>2021</b> , 21, 274-282	2.8	4
388	Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma. <i>Leukemia</i> , <b>2021</b> , 35, 3012-3016	10.7	3
387	Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. <i>IScience</i> , <b>2021</b> , 24, 102651	6.1	0
386	Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. <i>Blood</i> , <b>2021</b> , 137, 788-800	2.2	6
385	Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. <i>Nature</i> , <b>2021</b> , 589, 299-305	50.4	56
384	H1 histones control the epigenetic landscape by local chromatin compaction. <i>Nature</i> , <b>2021</b> , 589, 293-298	50.4	40
383	BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. <i>Blood</i> , <b>2021</b> , 137, 812-825	2.2	3
382	Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia. <i>Leukemia</i> , <b>2021</b> , 35, 2688-2692	10.7	2
381	An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. <i>Cancer Cell</i> , <b>2021</b> , 39, 240-256.e11	24.3	29
380	Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma. <i>Leukemia</i> , <b>2021</b> , 35, 1438-1450	10.7	8
379	Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1468-1489	24.4	27
378	OCT2 pre-positioning facilitates cell fate transition and chromatin architecture changes in humoral immunity. <i>Nature Immunology</i> , <b>2021</b> , 22, 1327-1340	19.1	3

377	Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 688493	8.4	2
376	Dissecting bulk transcriptomes of diffuse large B cell lymphoma. <i>Cancer Cell</i> , <b>2021</b> , 39, 1305-1307	24.3	1
375	DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation. <i>Nature Communications</i> , <b>2021</b> , 12, 5406	17.4	6
374	Histone H1 mutations in lymphoma: a link(er) between chromatin organization, developmental reprogramming, and cancer. <i>Cancer Research</i> , <b>2021</b> ,	10.1	3
373	Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1542-1561	24.4	30
372	Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. <i>Nature Immunology</i> , <b>2021</b> , 22, 240-253	19.1	12
371	Loss of function mutations of in classical Hodgkin lymphoma.. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-11	1.9	0
370	The SEQC2 epigenomics quality control (EpiQC) study. <i>Genome Biology</i> , <b>2021</b> , 22, 332	18.3	2
369	Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. <i>Cancer Cell</i> , <b>2020</b> , 37, 655-673.e11	24.3	47
368	TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis. <i>Science Advances</i> , <b>2020</b> , 6, eaay5872	14.3	12
367	The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing. <i>Nature Cancer</i> , <b>2020</b> , 1, 653-664	15.4	11
366	TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. <i>Cell</i> , <b>2020</b> , 182, 297-316.e27	56.2	23
365	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. <i>Cancer Discovery</i> , <b>2020</b> , 10, 440-459	24.4	54
364	The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 34-34	2.2	
363	BCL10 Gain-of-Function Mutations Aberrantly Induce Canonical and Non-Canonical NF-Kb Activation and Resistance to Ibrutinib in ABC-DLBCL. <i>Blood</i> , <b>2020</b> , 136, 2-3	2.2	3
362	Targeted detection and quantitation of histone modifications from 1,000 cells. <i>PLoS ONE</i> , <b>2020</b> , 15, e0240829	3.7	0
361	Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions <b>2020</b> ,		51
360	The therapeutic landscape for cells engineered with chimeric antigen receptors. <i>Nature Biotechnology</i> , <b>2020</b> , 38, 233-244	44.5	75

359	Clonal Hematopoiesis Before, During, and After Human Spaceflight. <i>Cell Reports</i> , <b>2020</b> , 33, 108458	10.6	6
358	Unique Immune Cell Coactivators Specify Locus Control Region Function and Cell Stage. <i>Molecular Cell</i> , <b>2020</b> , 80, 845-861.e10	17.6	9
357	Circulating miRNA Spaceflight Signature Reveals Targets for Countermeasure Development. <i>Cell Reports</i> , <b>2020</b> , 33, 108448	10.6	13
356	Multi-omic, Single-Cell, and Biochemical Profiles of Astronauts Guide Pharmacological Strategies for Returning to Gravity. <i>Cell Reports</i> , <b>2020</b> , 33, 108429	10.6	14
355	Cell-free DNA (cfDNA) and Exosome Profiling from a Year-Long Human Spaceflight Reveals Circulating Biomarkers. <i>iScience</i> , <b>2020</b> , 23, 101844	6.1	13
354	Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. <i>Blood Advances</i> , <b>2020</b> , 4, 5226-5231	7.8	12
353	The dangers of dJvu: memory B cells as the cells of origin of ABC-DLBCLs. <i>Blood</i> , <b>2020</b> , 136, 2263-2274	2.2	7
352	Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML. <i>Cancer Discovery</i> , <b>2020</b> , 10, 1934-1949	24.4	8
351	Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. <i>Genome Research</i> , <b>2020</b> , 30, 1217-1227	9.7	11
350	Epigenetic Mechanisms in Leukemias and Lymphomas. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2020</b> , 10,	5.4	5
349	The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy. <i>PLoS ONE</i> , <b>2020</b> , 15, e0231470	3.7	4
348	Targeted detection and quantitation of histone modifications from 1,000 cells <b>2020</b> , 15, e0240829		
347	Targeted detection and quantitation of histone modifications from 1,000 cells <b>2020</b> , 15, e0240829		
346	Targeted detection and quantitation of histone modifications from 1,000 cells <b>2020</b> , 15, e0240829		
345	Targeted detection and quantitation of histone modifications from 1,000 cells <b>2020</b> , 15, e0240829		
344	Targeted detection and quantitation of histone modifications from 1,000 cells <b>2020</b> , 15, e0240829		
343	Targeted detection and quantitation of histone modifications from 1,000 cells <b>2020</b> , 15, e0240829		
342	Targeted detection and quantitation of histone modifications from 1,000 cells <b>2020</b> , 15, e0240829		

341	Targeted detection and quantitation of histone modifications from 1,000 cells <b>2020</b> , 15, e0240829		
340	Dynamic Incorporation of Histone H3 Variants into Chromatin Is Essential for Acquisition of Aggressive Traits and Metastatic Colonization. <i>Cancer Cell</i> , <b>2019</b> , 36, 402-417.e13	24.3	37
339	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. <i>Cancer Discovery</i> , <b>2019</b> , 9, 546-563	24.4	123
338	Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. <i>Cancer Cell</i> , <b>2019</b> , 35, 916-931.e9	21.5	37
337	BCL6 modulates tissue neutrophil survival and exacerbates pulmonary inflammation following influenza virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 11888-11893	11.5	35
336	Quinoline and thiazolopyridine allosteric inhibitors of MALT1. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2019</b> , 29, 1694-1698	2.9	11
335	Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. <i>Cancer Discovery</i> , <b>2019</b> , 9, 872-889	24.4	22
334	Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. <i>Nature Communications</i> , <b>2019</b> , 10, 1874	17.4	38
333	The Impact of Heterogeneity on Single-Cell Sequencing. <i>Frontiers in Genetics</i> , <b>2019</b> , 10, 8	4.5	43
332	Emerging epigenetic-modulating therapies in lymphoma. <i>Nature Reviews Clinical Oncology</i> , <b>2019</b> , 16, 494-507	19.4	50
331	Germinal center-derived lymphomas: The darkest side of humoral immunity. <i>Immunological Reviews</i> , <b>2019</b> , 288, 214-239	11.3	64
330	The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight. <i>Science</i> , <b>2019</b> , 364,	33.3	300
329	PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. <i>Blood</i> , <b>2019</b> , 133, 2401-2412	2.2	29
328	Peptide-based covalent inhibitors of MALT1 paracaspase. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2019</b> , 29, 1336-1339	2.9	11
327	Ex vivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells. <i>Biomaterials</i> , <b>2019</b> , 198, 27-36	15.6	26
326	Rationale for targeting BCL6 in -rearranged acute lymphoblastic leukemia. <i>Genes and Development</i> , <b>2019</b> , 33, 1265-1279	12.6	8
325	Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. <i>Cancer Cell</i> , <b>2019</b> , 36, 194-209.e9	24.3	92
324	MTA2/NuRD Regulates B Cell Development and Cooperates with OCA-B in Controlling the Pre-B to Immature B Cell Transition. <i>Cell Reports</i> , <b>2019</b> , 28, 472-485.e5	10.6	11

323	Histone 1 Mutations Drive Lymphomagenesis By Inducing Primitive Stem Cell Functions and Epigenetic Instructions through Profound 3D Re-Organization of the B-Cell Genome. <i>Blood</i> , <b>2019</b> , 134, 23-23	2.2	1
322	Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling. <i>Blood</i> , <b>2019</b> , 134, 393-393	2.2	
321	Characterization of Complete Lncrnas Transcriptome Reveals Expression of Lncrnas As a Prognostic Factor and Linc-Smilo As a Potential Therapeutic Target in Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 4323-4323	2.2	2
320	Mapping MALT1 Signaling Connectivity Unveils Novel B-Cell Feedback Mechanisms Directing Assembly of Potent Anti-Lymphoma Regimens. <i>Blood</i> , <b>2019</b> , 134, 173-173	2.2	
319	Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas. <i>Blood</i> , <b>2019</b> , 134, 2073-2073	2.2	0
318	Rationale for Targeting BCL6 in MLL-Rearranged B-ALL. <i>Blood</i> , <b>2019</b> , 134, 1239-1239	2.2	
317	EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche. <i>Blood</i> , <b>2019</b> , 134, 2768-2768	2.2	0
316	Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response. <i>Nature Communications</i> , <b>2019</b> , 10, 821	17.4	49
315	BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress. <i>Cancer Discovery</i> , <b>2019</b> , 9, 662-679	24.4	19
314	An "EZ" Epigenetic Road to Leukemia Stem Cell Metabolic Reprogramming?. <i>Cancer Discovery</i> , <b>2019</b> , 9, 1158-1160	24.4	2
313	Role of chromosomal architecture in germinal center B cells and lymphomagenesis. <i>Current Opinion in Hematology</i> , <b>2019</b> , 26, 294-302	3.3	5
312	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. <i>Nature Immunology</i> , <b>2019</b> , 20, 86-96	19.1	39
311	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. <i>Blood</i> , <b>2019</b> , 133, 94-99	2.2	14
310	ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. <i>Cancer Cell</i> , <b>2018</b> , 33, 495-511.e12	24.3	148
309	How Biophysical Forces Regulate Human B Cell Lymphomas. <i>Cell Reports</i> , <b>2018</b> , 23, 499-511	10.6	19
308	MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , <b>2018</b> , 8, 478-497	24.4	37
307	AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. <i>Nature Communications</i> , <b>2018</b> , 9, 222	17.4	34
306	Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. <i>Cancer Cell</i> , <b>2018</b> , 33, 44-59.e8	24.3	53

305	Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis. <i>Blood</i> , <b>2018</b> , 132, 1265-1278	2.2	25
304	PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. <i>Blood</i> , <b>2018</b> , 132, 2026-2039	2.2	31
303	Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 4397-4412	15.9	33
302	Heat Shock Factor 1 Reprograms the DLBCL Microenvironment to Evade Immune Surveillance and Support Tumor Growth. <i>Blood</i> , <b>2018</b> , 132, 2854-2854	2.2	
301	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. <i>Cancer Discovery</i> , <b>2018</b> , 8, 1632-1653	24.4	77
300	Untangling the Role of Polycomb Complexes in Chemotherapy Resistance. <i>Cancer Discovery</i> , <b>2018</b> , 8, 1348-1351	24.4	2
299	Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design. <i>Journal of Medicinal Chemistry</i> , <b>2018</b> , 61, 7573-7588	8.3	22
298	Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model. <i>Cancer Research</i> , <b>2017</b> , 77, 1818-1830	10.1	10
297	is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells. <i>Blood</i> , <b>2017</b> , 129, 1779-1790	2.2	14
296	DNA Methylation-Based Biomarkers. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 793-795	2.2	6
295	BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. <i>Cancer Discovery</i> , <b>2017</b> , 7, 506-521	24.4	27
294	Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in - and -Mutant Acute Myeloid Leukemia. <i>Cancer Discovery</i> , <b>2017</b> , 7, 494-505	24.4	68
293	Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. <i>Cancer Discovery</i> , <b>2017</b> , 7, 868-883	24.4	69
292	Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. <i>Nature Genetics</i> , <b>2017</b> , 49, 866-875	36.3	53
291	Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. <i>Hematological Oncology</i> , <b>2017</b> , 35, 397-407	1.3	8
290	Modular Immune Organoids with Integrin Ligand Specificity Differentially Regulate Ex Vivo B Cell Activation. <i>ACS Biomaterials Science and Engineering</i> , <b>2017</b> , 3, 214-225	5.5	19
289	Untangling the Web of Lymphoma Somatic Mutations. <i>Cell</i> , <b>2017</b> , 171, 270-272	56.2	1
288	MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , <b>2017</b> , 77, 7038-7048	10.1	33



287	EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. <i>Nature Communications</i> , <b>2017</b> , 8, 877	17.4	87
286	The N-methyladenosine (m <sup>A</sup> )-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. <i>Nature Medicine</i> , <b>2017</b> , 23, 1369-1376	50.5	584
285	Genetic and epigenetic inactivation of controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	32
284	CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. <i>Cancer Discovery</i> , <b>2017</b> , 7, 38-53	24.4	159
283	The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 885-893	12.9	85
282	Central role of myeloid MCP1P1 in protecting against LPS-induced inflammation and lung injury. <i>Signal Transduction and Targeted Therapy</i> , <b>2017</b> , 2, 17066	21	37
281	SIRT3 Is a Novel Metabolic Driver of and Therapeutic Target for Chemotherapy Resistant Dlbcls. <i>Blood</i> , <b>2017</b> , 130, 643-643	2.2	2
280	m6a Regulates Differentiation State and mRNA Translation in Myeloid Leukemia. <i>Blood</i> , <b>2017</b> , 130, 791-791		
279	HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas. <i>Blood</i> , <b>2017</b> , 130, 645-645	2.2	
278	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 366ra161	17.5	109
277	Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region. <i>Immunity</i> , <b>2016</b> , 45, 497-512	32.3	82
276	Pathogenic role of B-cell receptor signaling and canonical NF- $\kappa$ B activation in mantle cell lymphoma. <i>Blood</i> , <b>2016</b> , 128, 82-92	2.2	92
275	Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation. <i>Epigenomics</i> , <b>2016</b> , 8, 945-57	4.4	17
274	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. <i>Nature Medicine</i> , <b>2016</b> , 22, 1488-1495	50.5	140
273	Roles for small noncoding RNAs in silencing of retrotransposons in the mammalian brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 12697-12702	11.5	52
272	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". <i>Nature Medicine</i> , <b>2016</b> , 22, 578-9	50.5	7
271	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. <i>Nature Medicine</i> , <b>2016</b> , 22, 792-9	50.5	217
270	PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. <i>Nature Medicine</i> , <b>2016</b> , 22, 379-87	50.5	74

269	A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. <i>JCI Insight</i> , <b>2016</b> , 1,	9.9	14
268	Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 3351-62	15.9	92
267	AICDA Introduces Epigenetic Plasticity in Germinal Center-Derived Lymphomas and Accelerates Lymphomagenesis. <i>Blood</i> , <b>2016</b> , 128, 1045-1045	2.2	1
266	Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age $\geq$ 60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial. <i>Blood</i> , <b>2016</b> , 128, 339-339	2.2	5
265	CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies. <i>Blood</i> , <b>2016</b> , 128, 4088-4088	2.2	2
264	Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. <i>Oncotarget</i> , <b>2016</b> , 7, 3520-32	3.3	20
263	Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis. <i>Blood</i> , <b>2016</b> , 128, 735-735	2.2	
262	Changes of the Mutational Landscape in Relapsed Acute Myeloid Leukemia. <i>Blood</i> , <b>2016</b> , 128, 599-599	2.2	
261	Hypermethylation of GADD45A Defines a Methylation Profile Distinct to Mutant IDH1/2, and Correlates with More Aggressive AML. <i>Blood</i> , <b>2016</b> , 128, 2877-2877	2.2	
260	RNA Interference Screen Implicates TNFAIP3 and FOXO1 in MALT1 Inhibition Resistance. <i>Blood</i> , <b>2016</b> , 128, 837-837	2.2	
259	Cooperative Gene Repression By DNA Methylation and LSD1-Mediated Enhancer Inactivation in Acute Myeloid Leukemia. <i>Blood</i> , <b>2016</b> , 128, 1048-1048	2.2	
258	Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-Rearranged Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 907-907	2.2	
257	BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation. <i>Blood</i> , <b>2016</b> , 128, 438-438	2.2	
256	RNA Binding Protein Syncrip Regulates the Leukemia Stem Cell Program. <i>Blood</i> , <b>2016</b> , 128, 739-739	2.2	
255	EZH2 Enables the Proliferation of Germinal Center B Cells and DLBCL through a Rb-E2F1 Positive Feedback Loop Involving Repression of CDKN1A. <i>Blood</i> , <b>2016</b> , 128, 734-734	2.2	
254	General Biomarker Recommendations for Lymphoma. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	2
253	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. <i>Nature Communications</i> , <b>2016</b> , 7, 11889	17.4	32
252	DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia. <i>Cancer Discovery</i> , <b>2016</b> , 6, 501-15	24.4	53

251	The many layers of epigenetic dysfunction in B-cell lymphomas. <i>Current Opinion in Hematology</i> , <b>2016</b> , 23, 377-84	3.3	26
250	Genetic and epigenetic heterogeneity in acute myeloid leukemia. <i>Current Opinion in Genetics and Development</i> , <b>2016</b> , 36, 100-6	4.9	79
249	Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. <i>Blood</i> , <b>2016</b> , 127, 858-68	2.2	54
248	miR-181a negatively regulates NF- $\kappa$ B signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis. <i>Blood</i> , <b>2016</b> , 127, 2856-66	2.2	28
247	The epichaperome is an integrated chaperome network that facilitates tumour survival. <i>Nature</i> , <b>2016</b> , 538, 397-401	50.4	148
246	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. <i>Cancer Cell</i> , <b>2016</b> , 30, 197-213	24.3	150
245	SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents. <i>Cancer Research</i> , <b>2016</b> , 76, 5467-78	10.1	46
244	A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations. <i>Molecular Cell</i> , <b>2016</b> , 63, 711-719	17.6	83
243	Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. <i>Cancer Cell</i> , <b>2015</b> , 27, 409-25	24.3	81
242	Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , <b>2015</b> , 28, 114-28	24.3	78
241	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. <i>Nature</i> , <b>2015</b> , 521, 357-61	50.4	90
240	BCL6 orchestrates Tfh cell differentiation via multiple distinct mechanisms. <i>Journal of Experimental Medicine</i> , <b>2015</b> , 212, 539-53	16.6	156
239	Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. <i>Nature Communications</i> , <b>2015</b> , 6, 6471	17.4	31
238	Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. <i>Cancer Cell</i> , <b>2015</b> , 27, 502-15	24.3	145
237	Epigenomic evolution in diffuse large B-cell lymphomas. <i>Nature Communications</i> , <b>2015</b> , 6, 6921	17.4	81
236	Loss of BAP1 function leads to EZH2-dependent transformation. <i>Nature Medicine</i> , <b>2015</b> , 21, 1344-9	50.5	231
235	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. <i>Journal of Experimental Medicine</i> , <b>2015</b> , 212, 1819-32	16.6	106
234	DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. <i>Cell Reports</i> , <b>2015</b> , 12, 2086-96	10.8	68

233	The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. <i>Nature Medicine</i> , <b>2015</b> , 21, 1199-208	50.5	247
232	Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. <i>Biomaterials</i> , <b>2015</b> , 73, 110-9	15.6	49
231	Transcriptome sequencing reveals thousands of novel long non-coding RNAs in B cell lymphoma. <i>Genome Medicine</i> , <b>2015</b> , 7, 110	14.4	50
230	A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. <i>Cell Reports</i> , <b>2015</b> , 13, 2159-73	10.6	41
229	VII. Are lymphomas driven by epigenetic lesions?. <i>Hematological Oncology</i> , <b>2015</b> , 33 Suppl 1, 42-5	1.3	
228	The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. <i>Blood</i> , <b>2015</b> , 125, 13-21	2.2	129
227	A roadmap for discovery and translation in lymphoma. <i>Blood</i> , <b>2015</b> , 125, 2175-7	2.2	16
226	Enhanced reduced representation bisulfite sequencing for assessment of DNA methylation at base pair resolution. <i>Journal of Visualized Experiments</i> , <b>2015</b> , e52246	1.6	65
225	VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma. <i>Journal of Visualized Experiments</i> , <b>2015</b> , e53215	1.6	5
224	Engineering of a Histone-Recognition Domain in Dnmt3a Alters the Epigenetic Landscape and Phenotypic Features of Mouse ESCs. <i>Molecular Cell</i> , <b>2015</b> , 59, 89-103	17.6	56
223	Mechanisms of action of BCL6 during germinal center B cell development. <i>Science China Life Sciences</i> , <b>2015</b> , 58, 1226-32	8.5	23
222	The epigenetic basis of diffuse large B-cell lymphoma. <i>Seminars in Hematology</i> , <b>2015</b> , 52, 86-96	4	32
221	Whole-genome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. <i>Genome Research</i> , <b>2015</b> , 25, 478-87	9.7	92
220	Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 1286-98	15.9	64
219	Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 4559-71	15.9	34
218	CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 1434-1434	2.2	3
217	North American Leukemia, Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy, and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥ 60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906). <i>Blood</i> , <b>2015</b> , 126, 217-217	2.2	24
216	Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia. <i>Blood</i> , <b>2015</b> , 126, 306-306	2.2	2

215	Transcriptome Sequencing Reveals Thousands of Novel Long Non-Coding RNAs in B-Cell Lymphoma. <i>Blood</i> , <b>2015</b> , 126, 2427-2427	2.2	
214	A Chromatin Reader That Acts As a Key to Lock in and Coordinate Recruitment of Transcription Factors and a Novel Polycomb Complex to Bivalent Chromatin Thus Driving Formation of Germinal Centers and B-Cell Lymphomas. <i>Blood</i> , <b>2015</b> , 126, 434-434	2.2	
213	Dose-Dependent Role of the Cohesin Complex in Normal and Malignant Hematopoiesis. <i>Blood</i> , <b>2015</b> , 126, 435-435	2.2	
212	Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL. <i>Blood</i> , <b>2015</b> , 126, 1422-1422	2.2	
211	Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 3716-3716	2.2	
210	Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 556-556	2.2	
209	Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. <i>Cancer Research</i> , <b>2014</b> , 74, 2520-32	10.1	170
208	Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. <i>Trends in Molecular Medicine</i> , <b>2014</b> , 20, 343-52	11.5	114
207	Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications. <i>Cellular and Molecular Bioengineering</i> , <b>2014</b> , 7, 394-408	3.9	29
206	Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1242-8	2.2	187
205	Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, E2219-28	11.5	64
204	Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 238ra71	17.5	82
203	Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer. <i>ACS Chemical Biology</i> , <b>2014</b> , 9, 1698-705	4.9	17
202	Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. <i>Nature Communications</i> , <b>2014</b> , 5, 3904	17.4	64
201	Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. <i>Blood</i> , <b>2014</b> , 123, 1699-708	2.2	63
200	Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. <i>Blood</i> , <b>2014</b> , 123, 3327-35	2.2	45
199	Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation. <i>Blood</i> , <b>2014</b> , 123, 1012-20	2.2	68
198	Histone deacetylase inhibitor treatment induces BRCAness and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. <i>Oncotarget</i> , <b>2014</b> , 5, 5637-50	3.3	110

197	The BCL6 RD2 domain governs commitment of activated B cells to form germinal centers. <i>Cell Reports</i> , <b>2014</b> , 8, 1497-508	10.6	46
196	Dynamic evolution of clonal epialleles revealed by methclone. <i>Genome Biology</i> , <b>2014</b> , 15, 472	18.3	48
195	DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. <i>Cell Reports</i> , <b>2014</b> , 9, 1841-1855	10.6	183
194	CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. <i>Cell Reports</i> , <b>2014</b> , 7, 1020-9	10.6	113
193	HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 1158-67	15.9	34
192	BCL6 Orchestrates Tfh Differentiation Via Multiple Distinct Mechanisms. <i>Blood</i> , <b>2014</b> , 124, 4137-4137	2.2	1
191	AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo. <i>Blood</i> , <b>2014</b> , 124, 437-437	2.2	15
190	Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host Disease (cGVHD) Using Direct and Epigenomic Therapies. <i>Blood</i> , <b>2014</b> , 124, 535-535	2.2	2
189	BCL6 Mediates a Stress Tolerance Phenotype through Its BTB Domain. <i>Blood</i> , <b>2014</b> , 124, 567-567	2.2	1
188	IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2014</b> , 124, 788-788	2.2	1
187	A Virtual B Cell Lymphoma Model to Predict Effective Combination Therapy. <i>Blood</i> , <b>2014</b> , 124, 928-928	2.2	2
186	Erk and Stat5 Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2014</b> , 124, 787-787	2.2	
185	PTEN Is Essential for Normal Cytokine Signaling and Oncogenic Transformation of Pre-B Cells. <i>Blood</i> , <b>2014</b> , 124, 262-262	2.2	
184	Hsp90 at the Hub of Metabolic Homeostasis in Malignant B Cells. <i>Blood</i> , <b>2014</b> , 124, 1764-1764	2.2	
183	BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2014</b> , 124, 3570-3570	2.2	
182	Conditional Loss of Dnmt3a Results in Myeloproliferation and Liver-Specific Myeloid Expansion. <i>Blood</i> , <b>2014</b> , 124, 364-364	2.2	
181	Mirna-181a expression Lead to Longer Animal Survival and Slower Tumor-Growth Rate in Diffuse Large B-Cell Lymphoma Xenograft Models. <i>Blood</i> , <b>2014</b> , 124, 2963-2963	2.2	
180	BACH2 promotes Lineage-Specific Fate Decisions in BCR-ABL1-Driven Leukemia. <i>Blood</i> , <b>2014</b> , 124, 513-513		

179	Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2014</b> , 124, 792-792	2.2	
178	Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2014</b> , 124, 284-284	2.2	
177	Msi2 Maintains the MLL Leukemia Stem Cell Regulatory Program. <i>Blood</i> , <b>2014</b> , 124, 836-836	2.2	
176	DNA Hydroxymethylation Profiling Reveals That WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. <i>Blood</i> , <b>2014</b> , 124, 365-365	2.2	
175	The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation. <i>Blood</i> , <b>2014</b> , 124, 69-69	2.2	
174	Hyperactive Ptpn11 Mutations Alters Leukemic Stem Cell Frequency through Mcl-1 Overexpression. <i>Blood</i> , <b>2014</b> , 124, 3565-3565	2.2	
173	Whole-Genome Epigenomic Analysis in Multiple Myeloma Reveals DNA Hypermethylation of B-Cell Specific Enhancers. <i>Blood</i> , <b>2014</b> , 124, 2032-2032	2.2	
172	A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. <i>Nature</i> , <b>2013</b> , 500, 93-7	50.4	103
171	New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes. <i>Current Opinion in Immunology</i> , <b>2013</b> , 25, 339-46	7.8	48
170	A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. <i>Cell Reports</i> , <b>2013</b> , 4, 578-88	10.6	127
169	Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. <i>Critical Reviews in Oncology/Hematology</i> , <b>2013</b> , 88, 231-45	7	23
168	DNMT1-interacting RNAs block gene-specific DNA methylation. <i>Nature</i> , <b>2013</b> , 503, 371-6	50.4	379
167	SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. <i>Blood</i> , <b>2013</b> , 121, 148-55	2.2	48
166	BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. <i>Nature Medicine</i> , <b>2013</b> , 19, 1014-22	50.5	82
165	DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at Alu elements during B-cell activation. <i>Genome Research</i> , <b>2013</b> , 23, 2030-41	9.7	75
164	LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas. <i>British Journal of Haematology</i> , <b>2013</b> , 162, 621-30	4.5	30
163	Negative regulation of osteoclast precursor differentiation by CD11b and $\alpha$ integrin-B-cell lymphoma 6 signaling. <i>Journal of Bone and Mineral Research</i> , <b>2013</b> , 28, 135-49	6.3	38
162	PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex. <i>Cell Reports</i> , <b>2013</b> , 5, 1625-38	10.6	59

161	Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly. <i>Molecular Cell</i> , <b>2013</b> , 51, 766-79	17.6	123
160	Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. <i>Nature Immunology</i> , <b>2013</b> , 14, 380-8	19.1	88
159	Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. <i>Nature Immunology</i> , <b>2013</b> , 14, 437-45	19.1	67
158	EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. <i>Cancer Cell</i> , <b>2013</b> , 23, 677-92	24.3	547
157	Discovering what makes STAT signaling TYK in T-ALL. <i>Cancer Discovery</i> , <b>2013</b> , 3, 494-6	24.4	3
156	Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. <i>Cancer Discovery</i> , <b>2013</b> , 3, 1002-19	24.4	140
155	Differentiation therapy for IDH1/2 mutant malignancies. <i>Cell Research</i> , <b>2013</b> , 23, 975-7	24.7	8
154	Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003137	6	91
153	Notch activation inhibits AML growth and survival: a potential therapeutic approach. <i>Journal of Experimental Medicine</i> , <b>2013</b> , 210, 321-37	16.6	109
152	Induction of sarcomas by mutant IDH2. <i>Genes and Development</i> , <b>2013</b> , 27, 1986-98	12.6	114
151	Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. <i>Cancer Research</i> , <b>2013</b> , 73, 1076-85	10.1	44
150	Molecular pathways: targeting MALT1 paracaspase activity in lymphoma. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6662-8	12.9	22
149	Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. <i>Cancer Research</i> , <b>2013</b> , 73, 1232-44	10.1	137
148	Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. <i>Blood</i> , <b>2013</b> , 121, 5192-202	2.2	66
147	Downregulation of FOXP1 is required during germinal center B-cell function. <i>Blood</i> , <b>2013</b> , 121, 4311-20	2.2	47
146	BCL6 breaks occur at different AID sequence motifs in Ig-BCL6 and non-Ig-BCL6 rearrangements. <i>Blood</i> , <b>2013</b> , 121, 4551-4	2.2	27
145	Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 3099-111	15.9	88
144	EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains. <i>Blood</i> , <b>2013</b> , 122, 1-1	2.2	12



143	Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. <i>Blood</i> , <b>2013</b> , 122, 3736-3736	2.2	1
142	Epigenomic Evolution In Diffuse Large B-Cell Lymphomas. <i>Blood</i> , <b>2013</b> , 122, 634-634	2.2	2
141	Deep Sequencing Reveals Clonal Evolution Patterns and Mutation Events Associated With Relapse In B Cell Lymphomas. <i>Blood</i> , <b>2013</b> , 122, 79-79	2.2	1
140	High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R. <i>Blood</i> , <b>2013</b> , 122, 3760-3760	2.2	
139	Dynamic Changes Of DNA Methylation and a Functional Role For TET2 DNA Dioxygenase In Human Erythroid Differentiation. <i>Blood</i> , <b>2013</b> , 122, 3415-3415	2.2	1
138	The Bcl6 RD2 Domain Is Essential For Pre-Germinal Center B Cell Development. <i>Blood</i> , <b>2013</b> , 122, 783-783		
137	Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia. <i>Blood</i> , <b>2013</b> , 122, 229-229	2.2	
136	Epigenetic Deregulation In Relapsed Acute Myeloid Leukemia. <i>Blood</i> , <b>2013</b> , 122, 2499-2499	2.2	1
135	The Histone Demethylase LSD1 Acts As a BCL6 Corepressor In Germinal Center B Cells. <i>Blood</i> , <b>2013</b> , 122, 781-781	2.2	1
134	Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL. <i>Blood</i> , <b>2013</b> , 122, 72-72	2.2	
133	Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. <i>Blood</i> , <b>2012</b> , 119, 5478-91	2.2	32
132	Epigenetic therapy leaps ahead with specific targeting of EZH2. <i>Cancer Cell</i> , <b>2012</b> , 22, 569-70	24.3	20
131	Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. <i>Nature Genetics</i> , <b>2012</b> , 44, 1179-81	36.3	552
130	ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. <i>Cancer Cell</i> , <b>2012</b> , 22, 180-93	24.3	416
129	A molecular roadmap of reprogramming somatic cells into iPS cells. <i>Cell</i> , <b>2012</b> , 151, 1617-32	56.2	620
128	methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. <i>Genome Biology</i> , <b>2012</b> , 13, R87	18.3	893
127	H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia. <i>Cancer Cell</i> , <b>2012</b> , 22, 194-208	24.3	31
126	MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. <i>Cancer Cell</i> , <b>2012</b> , 22, 812-24	24.3	182

125	The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. <i>Cell Metabolism</i> , <b>2012</b> , 15, 554-62	24.6	90
124	Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , <b>2012</b> , 51, 1125-32	5	28
123	IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. <i>Nature</i> , <b>2012</b> , 488, 656-9	50.4	395
122	Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1079-89	59.2	1378
121	IDH mutation impairs histone demethylation and results in a block to cell differentiation. <i>Nature</i> , <b>2012</b> , 483, 474-8	50.4	1393
120	Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. <i>Blood</i> , <b>2012</b> , 119, 5824-31	2.2	193
119	Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. <i>PLoS Genetics</i> , <b>2012</b> , 8, e1002781	6	223
118	Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. <i>Cancer Discovery</i> , <b>2012</b> , 2, 1004-23	24.4	70
117	Oncogene-mediated alterations in chromatin conformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 9083-8	11.5	110
116	C/EBP $\beta$ deregulation results in differentiation arrest in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 4490-504	15.9	43
115	Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma. <i>PLoS ONE</i> , <b>2012</b> , 7, e40332	3.7	39
114	MiR-181a Is a Master Regulator of the Nuclear Factor- $\kappa$ B Signaling Pathway in Diffuse Large B Cell Lymphoma. <i>Blood</i> , <b>2012</b> , 120, 417-417	2.2	
113	BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance. <i>Blood</i> , <b>2012</b> , 120, 1300-1300	2.2	
112	H2.0-Like Homeobox (HLX) Induces Unlimited Clonogenicity, Blocks Differentiation, and Cooperates with FLT3-ITD in the Induction of Acute Myeloid Leukemia. <i>Blood</i> , <b>2012</b> , 120, 651-651	2.2	
111	Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL. <i>Blood</i> , <b>2012</b> , 120, 776-776	2.2	
110	Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases. <i>Blood</i> , <b>2012</b> , 120, 1352-1352	2.2	
109	Next Gen Dissection of Gfi1 Dependent Transcriptome in Myeloid Progenitors Reveals Global Control of Multiple Transcriptional Programs Including Coding and Non Coding RNAs. <i>Blood</i> , <b>2012</b> , 120, 111-111	2.2	
108	Enhancer Profiling Reveals SOX9 As a Novel Transcription Regulator of B Cell Activation and DLBCL Transformation. <i>Blood</i> , <b>2012</b> , 120, 527-527	2.2	

107	Lineage, Fusion Partner and Age Differences in the Methylome of MLL-r Leukemias. <i>Blood</i> , <b>2012</b> , 120, 3506-3506	2.2	
106	Combinatorial Targeting of BCL6 and Anti-Apoptotic Proteins in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , <b>2012</b> , 120, 64-64	2.2	
105	The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. <i>Cell</i> , <b>2011</b> , 147, 554-64	56.2	139
104	Epigenetics and B-cell lymphoma. <i>Current Opinion in Hematology</i> , <b>2011</b> , 18, 293-9	3.3	54
103	Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. <i>Blood</i> , <b>2011</b> , 117, 234-41	2.2	82
102	SYK inhibition and response prediction in diffuse large B-cell lymphoma. <i>Blood</i> , <b>2011</b> , 118, 6342-52	2.2	82
101	BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. <i>Nature</i> , <b>2011</b> , 473, 384-8	50.4	154
100	Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. <i>Cancer Cell</i> , <b>2011</b> , 20, 11-24	24.3	876
99	DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. <i>Blood</i> , <b>2011</b> , 118, 3559-69	2.2	107
98	The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. <i>Science</i> , <b>2011</b> , 333, 765-9	33.3	161
97	Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 25211-23	5.4	38
96	BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. <i>Journal of Experimental Medicine</i> , <b>2011</b> , 208, 2163-74	16.6	138
95	Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. <i>Nature Chemical Biology</i> , <b>2011</b> , 7, 818-26	11.7	208
94	LITAF, a BCL6 Target Gene, Regulates Autophagia in B Cells and Is Essential for T-Cell Dependent Humoral Responses. <i>Blood</i> , <b>2011</b> , 118, 1391-1391	2.2	1
93	DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell Survival. <i>Blood</i> , <b>2011</b> , 118, 1479-1479	2.2	1
92	ASXL1 Mutations Promote Myeloid Transformation Through Inhibition of PRC2-Mediated Gene Repression. <i>Blood</i> , <b>2011</b> , 118, 405-405	2.2	3
91	Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. <i>PLoS Genetics</i> , <b>2011</b> , 7, e1001356	6	91
90	Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. <i>PLoS ONE</i> , <b>2011</b> , 6, e18436	3.7	34

89	BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia. <i>Blood</i> , <b>2011</b> , 118, 446-446	2.2	
88	Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues. <i>Blood</i> , <b>2011</b> , 118, 1617-1617	2.2	
87	Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYC. <i>Blood</i> , <b>2011</b> , 118, 1406-1406	2.2	
86	Identification of LMO2 Transcriptome and Interactome in Diffuse Large B-Cell Lymphoma by Integrated Experimental and Computational Approach. <i>Blood</i> , <b>2011</b> , 118, 438-438	2.2	
85	Development of Acute Megakaryoblastic Leukemia in Down Syndrome Is Associated with Sequential Epigenetic Changes That Target the Down Syndrome Critical Region on Chromosome 21,. <i>Blood</i> , <b>2011</b> , 118, 3451-3451	2.2	1
84	Therapeutic Targeting of Lymphoma-Associated Vascular Pericytes,. <i>Blood</i> , <b>2011</b> , 118, 3725-3725	2.2	0
83	Gene Risk Scores Based on Expression of 6 Genes Quantitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study. <i>Blood</i> , <b>2011</b> , 118, 87-87	2.2	
82	A Role for BCL6 in the Higher-Order Organization of Genes in DLBCL. <i>Blood</i> , <b>2011</b> , 118, 558-558	2.2	
81	Conserved Transcriptional Deregulation Underlies GFI1 and ELANE Mutant Neutropenia. <i>Blood</i> , <b>2011</b> , 118, 13-13	2.2	1
80	BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2011</b> , 118, 562-562	2.2	
79	Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis. <i>Blood</i> , <b>2011</b> , 118, 556-556	2.2	
78	Genomewide Detection of Genes Targeted by Aberrant Somatic Hypermutation in Lymphoma,. <i>Blood</i> , <b>2011</b> , 118, 3474-3474	2.2	
77	High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma. <i>Blood</i> , <b>2011</b> , 118, 585-585	2.2	
76	Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. <i>Nature Biotechnology</i> , <b>2010</b> , 28, 848-55	44.5	949
75	SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 3608-3616	5.4	25
74	DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. <i>Cancer Research</i> , <b>2010</b> , 70, 5840-50	10.1	51
73	BCL6 is critical for the development of a diverse primary B cell repertoire. <i>Journal of Experimental Medicine</i> , <b>2010</b> , 207, 1209-21	16.6	89
72	Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2435-42	12.9	23

71	Genome-wide analysis of DNA binding and transcriptional regulation by the mammalian Doublesex homolog DMRT1 in the juvenile testis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 13360-5	11.5	79
70	Epigenetics in AML. <i>Best Practice and Research in Clinical Haematology</i> , <b>2010</b> , 23, 463-8	4.2	21
69	NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> ,	4.7	28
68	Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. <i>Blood</i> , <b>2010</b> , 115, 4798-809	2.2	94
67	Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. <i>Blood</i> , <b>2010</b> , 116, 1025-34	2.2	120
66	EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. <i>Blood</i> , <b>2010</b> , 116, 5247-55	2.2	227
65	DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. <i>Blood</i> , <b>2010</b> , 116, e81-9	2.2	124
64	DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. <i>Cancer Cell</i> , <b>2010</b> , 17, 13-27	24.3	640
63	A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. <i>Cancer Cell</i> , <b>2010</b> , 17, 400-11	24.3	230
62	Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. <i>Cancer Cell</i> , <b>2010</b> , 18, 553-67	24.3	1933
61	BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 4569-82	15.9	88
60	BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia. <i>Blood</i> , <b>2010</b> , 116, 202-202	2.2	0
59	High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial. <i>Blood</i> , <b>2010</b> , 116, 851-851	2.2	1
58	STAT3, Constitutively Activated In ABC-Like DLBCL, Regulates Expression of the Prognostic Factor Cyclin D2. <i>Blood</i> , <b>2010</b> , 116, 705-705	2.2	
57	Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 8368-73	11.5	255
56	Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells. <i>Cancer Research</i> , <b>2009</b> , 69, 55-64	10.1	24
55	High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. <i>Nucleic Acids Research</i> , <b>2009</b> , 37, 3829-39	20.1	133
54	A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. <i>Nature Medicine</i> , <b>2009</b> , 15, 1369-76	50.5	136

53	Outcome of deferred initial therapy in mantle-cell lymphoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1209-13	270
52	Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. <i>Blood</i> , <b>2009</b> , 113, 2795-804	2.2 74
51	A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. <i>Blood</i> , <b>2009</b> , 113, 3397-405	2.2 142
50	The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. <i>Blood</i> , <b>2009</b> , 113, 5536-48	2.2 179
49	MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. <i>Blood</i> , <b>2009</b> , 114, 3448-58	2.2 268
48	BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROT. <i>Blood</i> , <b>2009</b> , 114, 5315-21	2.2 48
47	BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia.. <i>Blood</i> , <b>2009</b> , 114, 765-765	2.2
46	Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy.. <i>Blood</i> , <b>2009</b> , 114, 673-673	2.2
45	DNA Methylation Profiling Predicts Clinical Outcomes and Reveals Unique Insights Into the Molecular Complexity of Acute Myeloid Leukemia.. <i>Blood</i> , <b>2009</b> , 114, 707-707	2.2
44	BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire.. <i>Blood</i> , <b>2009</b> , 114, 91-91	2.2
43	Promoter Hypermethylation in MLL-r Leukemia: Biology and Therapeutic Targeting.. <i>Blood</i> , <b>2009</b> , 114, 3472-3472	2.2
42	EZH2 Mediates DNA Methylation-Independent Epigenetic Silencing of a Germinal Center Specific Transcriptional Program That Contributes to Cellular Proliferation and Lymphomagenesis.. <i>Blood</i> , <b>2009</b> , 114, 3465-3465	2.2 1
41	ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures.. <i>Blood</i> , <b>2009</b> , 114, 619-619	2.2
40	BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia.. <i>Blood</i> , <b>2009</b> , 114, 2167-2167	2.2 1
39	Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer. <i>Molecular Cell</i> , <b>2008</b> , 29, 384-91	17.6 112
38	BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. <i>Blood Cells, Molecules, and Diseases</i> , <b>2008</b> , 41, 95-9	2.1 71
37	Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 874-82	1.9 35
36	Sequential transcription factor targeting for diffuse large B-cell lymphomas. <i>Cancer Research</i> , <b>2008</b> , 68, 3361-9	10.1 26

35	BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 22565-72	5.4	32
34	CtBP is an essential corepressor for BCL6 autoregulation. <i>Molecular and Cellular Biology</i> , <b>2008</b> , 28, 2175-88	4.8	45
33	Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines. <i>Cancer Research</i> , <b>2008</b> , 68, 7258-63	10.1	83
32	Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells. <i>Blood</i> , <b>2008</b> , 112, 644-51	2.2	28
31	B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. <i>Current Opinion in Hematology</i> , <b>2008</b> , 15, 381-90	3.3	60
30	Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration. <i>PLoS ONE</i> , <b>2008</b> , 3, e2965	3.7	18
29	BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2008</b> , 112, 295-295	2.2	2
28	Epigenetic Determinants of Pathogenesis and Resistance to Proteasome Inhibition in Mantle Cell Lymphoma.. <i>Blood</i> , <b>2008</b> , 112, 3373-3373	2.2	1
27	Epigenetic Signatures Identify New Clinically Relevant Subtypes and Define Gene Regulatory Patterns in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2008</b> , 112, 756-756	2.2	2
26	Two Different EVI1 Expressing Poor-Risk AML Subgroups with Distinct Epigenetic Signatures Uncovered by Genome Wide DNA Methylation Profiling. <i>Blood</i> , <b>2008</b> , 112, 757-757	2.2	3
25	An integrative genomic and epigenomic approach for the study of transcriptional regulation. <i>PLoS ONE</i> , <b>2008</b> , 3, e1882	3.7	72
24	Antitumor Efficacy of the Purine-Scaffold Hsp90 Inhibitor PU-H71 in Diffuse Large-B Cell Lymphoma. <i>Blood</i> , <b>2008</b> , 112, 602-602	2.2	
23	Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. <i>Nature Immunology</i> , <b>2007</b> , 8, 705-14	19.1	200
22	Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 3207-12	11.5	115
21	CG dinucleotide clustering is a species-specific property of the genome. <i>Nucleic Acids Research</i> , <b>2007</b> , 35, 6798-807	20.1	67
20	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. <i>Blood</i> , <b>2007</b> , 110, 2067-74	2.2	110
19	Myelodysplastic Syndrome (MDS) Displays Profound and Functionally Significant Epigenetic Dereglulation Compared to Acute Myeloid Leukemia (AML) and Normal Bone Marrow Cells.. <i>Blood</i> , <b>2007</b> , 110, 345-345	2.2	
18	Kaiso-deficient mice show resistance to intestinal cancer. <i>Molecular and Cellular Biology</i> , <b>2006</b> , 26, 199-208	4.8	136

17	Comparative isoschizomer profiling of cytosine methylation: the HELP assay. <i>Genome Research</i> , <b>2006</b> , 16, 1046-55	9.7	330
16	Specific peptides for the therapeutic targeting of oncogenes. <i>Current Opinion in Genetics and Development</i> , <b>2006</b> , 16, 71-7	4.9	28
15	A BCL6 Target Gene Signature Predicts the Biological Behavior and Classification of Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , <b>2006</b> , 108, 616-616	2.2	
14	Reprogramming Specific Gene Expression Pathways in B-Cell Lymphomas. <i>Cell Cycle</i> , <b>2005</b> , 4, 241-243	4.7	6
13	The theoretical basis of transcriptional therapy of cancer: can it be put into practice?. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3957-70	2.2	28
12	Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. <i>Nature Medicine</i> , <b>2004</b> , 10, 1329-35	50.5	251
11	ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. <i>Blood</i> , <b>2004</b> , 103, 1454-63	2.2	66
10	The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. <i>Blood</i> , <b>2004</b> , 103, 4650-8	2.2	39
9	Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. <i>Best Practice and Research in Clinical Haematology</i> , <b>2003</b> , 16, 387-408	4.2	32
8	Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. <i>Molecular Cell</i> , <b>2003</b> , 12, 1551-64	17.6	211
7	Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. <i>Molecular and Cellular Biology</i> , <b>2002</b> , 22, 1804-18	4.8	177
6	Histone deacetylases as therapeutic targets in hematologic malignancies. <i>Current Opinion in Hematology</i> , <b>2002</b> , 9, 322-32	3.3	92
5	Translocations of the RARalpha gene in acute promyelocytic leukemia. <i>Oncogene</i> , <b>2001</b> , 20, 7186-203	9.2	190
4	The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. <i>Molecular and Cellular Biology</i> , <b>2000</b> , 20, 2075-86	4.8	125
3	In-Depth Mutational Analysis of the Promyelocytic Leukemia Zinc Finger BTB/POZ Domain Reveals Motifs and Residues Required for Biological and Transcriptional Functions. <i>Molecular and Cellular Biology</i> , <b>2000</b> , 20, 6550-6567	4.8	5
2	The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. <i>Molecular and Cellular Biology</i> , <b>1998</b> , 18, 5533-45	4.8	150
1	KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas		1